(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/46189 A1

(51) International Patent Classification[7]: C07D 471/04, 403/04, 403/14, 413/04, A61K 31/55, A61P 1/06 // (C07D 471/04, 221:00, 235:00)

(21) International Application Number: PCT/EP00/12858

(22) International Filing Date:
14 December 2000 (14.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99204441.2 21 December 1999 (21.12.1999) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JANSSENS, Frans, Eduard** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; Janssen Cilag S.A, 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux (FR). **SOMMEN, François, Maria** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: **DE CORTE, Filip**; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS



(I)

(57) Abstract: The present invention relates to compounds of formula (I), their prodrugs, *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms, wherein the bivalent radical -A- represents a saturated or an unsaturated homopiperidinyl having one double bond, and wherein said bivalent radical -A- is substituted with R^2 being hydrogen, hydroxy, C_{1-4}alkyl, or C_{1-4}alkyloxy; $-a^1=a^2-a^3=a^4-$ represents an optionally substituted bivalent radical; R^1 is hydrogen, C_{1-6}alkyl, aryl^1, C_{1-6}alkyl substituted with aryl^1, C_{1-4}alkyloxycarbonyl, aryl^{1}carbonyl, aryl$^1C_{1-6}$alkylarbonyl C_{1-4}alkylcarbonyl, trifluoromethyl, trifluoromethylcarbonyl, C_{1-6}alkylsulfonyl, aryl^{1}sulfonyl, methanesulfonyl, benzenesulfonyl, trifluoromethanesulfonyl, dimethylsulfamoyl; X represents O, S or NR^3, wherein R^3 is hydrogen, C_{1-6}alkyl, methanesulfonyl, benzenesulfonyl, trifluoromethanesulfonyl, dimethylsulfamoyl, C_{1-4}alkyl substituted with aryl^2 and optionally with hydroxy, C_{1-4}alkylcarbonylC_{1-4}alkyl substituted with aryl^2; aryl^1 is optionally substituted phenyl, optionally substituted pyridinyl, naphthyl, quinolinyl, or 1,3-benzodioxolyl; aryl^2 is optionally substituted phenyl; fundic relaxating activity. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating dyspeptic symptoms, irritable bowel syndrome and other conditions related to a hampered or impaired relaxation of the fundus.

WO 01/46189 A1